RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC).

Stephane  Champiat

Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda

Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; BeiGene; BioNTech SE; Celanese; Domain Therapeutics; Ellipses Pharma; Genmab; Immunicom; Mariana Oncology; Nanobiotix; NextCure; Oncovita; Pierre Fabre; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8

Research Funding - Abbvie; Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen; Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); BB Biotech Ventures (Inst); BBB Technologies (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics; Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); CellCentric (Inst); Centessa Pharmaceuticals; Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); CureVac (Inst); Cytovation; Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai/H3 Biomedicine; Exelixis (Inst); Faron Pharmaceuticals (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); ImCheck therapeutics; Immunocore; Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners; Molecular Partners (Inst); MSD; Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); OSE Immunotherapeutics; Ose Pharma (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre; Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); Relay Therapeutics (Inst); Replimune; RigonTEC (Inst); Roche (Inst); Roche (Inst); Roche/Genentech; Sanofi; Sanofi (Inst); Sanofi/Aventis (Inst); Seagen; Seagen (Inst); SERVIER (Inst); Sierra Oncology (Inst); Sotio; Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Transgene; Transgene (Inst); Turning Point Therapeutics (Inst); Veracyte (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2

Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio

Other Relationship - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NH TherAguix (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)

Patrick  Grierson

Employment - Walgreens (I)

Honoraria - AstraZeneca

Consulting or Advisory Role - AstraZeneca

Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer

Jason  Hsieh

No Relationships to Disclose

Masafumi  Ikeda

Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Guardant Health; Incyte; Lilly Japan; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma

Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)

Yu-Yun  Shao

Honoraria - AstraZeneca/MedImmune; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche

Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche

Research Funding - AstraZeneca/MedImmune; Roche

Travel, Accommodations, Expenses - Roche

Changhoon  Yoo

Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER

Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER

Cristina  Bergamaschi

Employment - AstraZeneca; Cartesian Therapeutics (I)

Stock and Other Ownership Interests  - AstraZeneca; Cartesian Therapeutics (I)

Research Funding - AstraZeneca; Cartersian Therapeutics (I)

Patents, Royalties, Other Intellectual Property - Cristina Bergamaschi is a listed inventor on US Government-owned patents related to heterodimeric IL-15. Cristina Cristina Bergamaschi is a listed inventor on an Astrazeneca patents related to AZD9793

Sarah  Blanchette

Employment - AstraZeneca/MedImmune

Stock and Other Ownership Interests  - AstraZeneca/MedImmune

Patents, Royalties, Other Intellectual Property - Ipsen (Inst)

Lyndon  Kirby

No Relationships to Disclose

Anna  Krotkova

Employment - AstraZeneca/MedImmune

Stock and Other Ownership Interests  - AstraZeneca/MedImmune

Elie  Pommier

Employment - AstraZeneca/MedImmune

Maria  Trissal

Employment - AstraZeneca; Takeda

Stock and Other Ownership Interests  - Takeda

Travel, Accommodations, Expenses - AstraZeneca; Takeda

Frederick  Goldberg

Employment - AstraZeneca/MedImmune

Stock and Other Ownership Interests  - AstraZeneca/MedImmune

Bharat  Burman

Employment - Janssen (I)

Stock and Other Ownership Interests  - Janssen (I)

Honoraria - Medscape

Stephen  Chan

Honoraria - AstraZeneca; Eisai; Elevar Therapeutics; Ipsen; MSD (Inst); Roche

Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Exelixis; MSD Oncology; Roche

Research Funding - Eisai; MSD

Travel, Accommodations, Expenses - Ipsen; Roche